Jim Cramer spoke with energy expert Rusty Braziel, who shed light on where the price of crude is headed in the long term. » Read More
Jim Cramer decoded Donald Trump’s tweets and identified stocks that were previously considered well-defended. » Read More
Jim Cramer went off the charts with the help of Rob Moreno, to measure the impact on interest rates, the dollar and inflation under Donald Trump. » Read More
Jim Cramer changes his tune on defense stocks based on recent tweets from the President-elect. » Read More
Jim Cramer called for bearish analysts that didn't back the Newell-Rubbermaid and Jarden merger to eat crow.
Jim Cramer compared the restaurant, retail and banking cohorts to where he thought they would be a year ago.
Tempur Sealy shares plunged more than 22 percent intraday Wednesday after the mattress maker handed in a disappointing full-year sales guidance.
UBS' John Hodulik, a top-rated analyst, downgraded AT&T to neutral from buy on Wednesday, reducing his 12-month price target by 7 percent to $43.
"Halftime Report" trader Jon Najarian bought Grupo Televisa for his CNBC PRO model portfolio.
BlackBerry jumped Wednesday after it posted earnings. The company also announced the departure of its CFO, James Yersh.
A flurry of Fed speakers, including the Fed chair, will keep markets busy Wednesday.
Nomura initiates coverage of Amazon with a buy rating.
The "Fast Money" traders looked for opportunities in consumer stocks after Nike's future orders disappointed Wall Street on Tuesday.
Mizuho just downgraded Twitter to underperform, citing extended valuations and skepticism over whether the social media company will be acquired.
Some of the names on the move ahead of the open.
Jim Cramer spoke with the CEO of Thor Industries following record sales of RVs on what could be steering growth.
Jim Cramer officially unveils his new acronym for red-hot growth stocks in the market.
Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.
Steven DeSanctis, one of the most widely followed small-cap strategists on Wall Street, discusses his top investment themes in the space.
Credit Suisse downgrades J.M. Smucker, maker of Kibbles 'n Bits dog food and Milk-Bone treats, to neutral from outperform.
Get the best of CNBC in your inbox